Recursion Pharmaceuticals, Inc.
RXRX
$6.35
$0.416.90%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 32.00% | 37.64% | -0.70% | -0.88% | 11.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.00% | 37.64% | -0.70% | -0.88% | 11.88% |
| Cost of Revenue | 26.72% | 26.47% | 37.28% | 36.15% | 39.14% |
| Gross Profit | -25.74% | -23.97% | -47.56% | -45.95% | -45.76% |
| SG&A Expenses | 60.76% | 30.14% | 34.57% | 41.63% | 31.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.28% | 27.50% | 36.52% | 37.66% | 36.85% |
| Operating Income | -36.83% | -25.98% | -43.24% | -44.54% | -40.86% |
| Income Before Tax | -39.94% | -30.89% | -46.27% | -44.26% | -38.69% |
| Income Tax Expenses | 72.23% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.33% | -29.12% | -44.21% | -42.31% | -36.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.33% | -29.12% | -44.21% | -42.31% | -36.99% |
| EBIT | -36.83% | -25.98% | -43.24% | -44.54% | -40.86% |
| EBITDA | -35.87% | -23.99% | -39.67% | -40.65% | -37.55% |
| EPS Basic | -5.65% | -5.48% | -18.89% | -17.32% | -15.05% |
| Normalized Basic EPS | -4.78% | -6.73% | -20.16% | -18.46% | -15.06% |
| EPS Diluted | -5.88% | -5.53% | -18.89% | -17.32% | -15.05% |
| Normalized Diluted EPS | -4.78% | -6.73% | -20.16% | -18.46% | -15.06% |
| Average Basic Shares Outstanding | 32.07% | 24.08% | 21.75% | 21.02% | 18.31% |
| Average Diluted Shares Outstanding | 32.07% | 24.08% | 21.75% | 21.02% | 18.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
